<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01553591</url>
  </required_header>
  <id_info>
    <org_study_id>27018966IBS3001</org_study_id>
    <secondary_id>2012-001600-38</secondary_id>
    <nct_id>NCT01553591</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Furiex Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Furiex Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy, safety, and tolerability of different
      doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants
      with diarrhea-predominant irritable bowel syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 29, 2012</start_date>
  <completion_date type="Actual">July 29, 2014</completion_date>
  <primary_completion_date type="Actual">July 29, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain And Daily Stool Consistency Scores</measure>
    <time_frame>Up to 12 Weeks</time_frame>
    <description>Composite responders were defined as a participant who met the daily response criteria for at least 50% of the days with diary entries during the interval of interest. A participant must had met both of the following criteria on a given day to be a daily responder: 1) Daily pain response: worst abdominal pain scores in the past 24 hours improved by ≥30% compared to baseline (average of daily worst abdominal pain the week prior to randomization). 2) Daily stool consistency response: Bristol Stool Scale (BSS) score &lt;5 (ie, score of 1, 2, 3, or 4) or the absence of a bowel movement if accompanied by ≥30% improvement in worst abdominal pain compared to baseline pain. Bristol stool scale was defined as 7-point Scale in which a score of 1 = separate hard lumps, 2 = sausage shaped but lumpy, 3 = sausage-like with cracks on the surface, 4 = sausage-like but smooth and soft, 5 = soft blobs with clear cut edges, 6 = fluffy pieces with ragged edges, and 7 = watery with no solid pieces.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain And Daily Stool Consistency Scores</measure>
    <time_frame>Up to 26 Weeks</time_frame>
    <description>Composite responders were defined as a participant who met the daily response criteria for at least 50% of the days with diary entries during the interval of interest. A participant must had met both of the following criteria on a given day to be a daily responder: 1) Daily pain response: worst abdominal pain scores in the past 24 hours improved by ≥30% compared to baseline (average of daily worst abdominal pain the week prior to randomization). 2) Daily stool consistency response: Bristol Stool Scale (BSS) score &lt;5 (ie, score of 1, 2, 3, or 4) or the absence of a bowel movement if accompanied by ≥30% improvement in worst abdominal pain compared to baseline pain. Bristol stool scale was defined as 7-point Scale in which a score of 1 = separate hard lumps, 2 = sausage shaped but lumpy, 3 = sausage-like with cracks on the surface, 4 = sausage-like but smooth and soft, 5 = soft blobs with clear cut edges, 6 = fluffy pieces with ragged edges, and 7 = watery with no solid pieces.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Pain Responders In Daily Worst Abdominal Pain Scores by Intervals</measure>
    <time_frame>12-week interval (Weeks 1-12), 26-week interval (Weeks 1-26), and 4-week interval (Weeks 1-4, 5-8, 9-12, 13-16, 17-20, and 21-24)</time_frame>
    <description>Pain responders were defined as participants who met the daily pain response criteria (ie, the worst abdominal pain score in the past 24 hours improved by ≥30% compared to baseline) for at least 50% of days with diary entries during each interval. A participant must have had a minimum of 20 days of diary entries over any 4-week interval, a minimum of 60 days of diary entries over the 12-week interval, and a minimum of 110 days of diary entries over the 26-week interval to be a responder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Responders In Daily Stool Consistency Scores by Intervals</measure>
    <time_frame>12-week interval (Weeks 1-12), 26-week interval (Weeks 1-26), and 4-week interval (Weeks 1-4, 5-8, 9-12, 13-16, 17-20, and 21-24)</time_frame>
    <description>Stool consistency responders: participants who met daily stool consistency response criterion (ie,score of 1, 2, 3, or 4 or absence of bowel movement if accompanied by ≥30% improvement in worst abdominal pain compared to baseline pain) for at least 50% of days with diary entries during each interval. BSS was defined as 7-point Scale in which score of 1= separate hard lumps, 2= sausage shaped but lumpy, 3= sausage-like with cracks on the surface, 4= sausage-like but smooth and soft, 5= soft blobs with clear cut edges, 6= fluffy pieces with ragged edges, and 7= watery with no solid pieces. A participant must have had a minimum of 20 days of diary entries over any 4-week interval, a minimum of 60 days of diary entries over 12-week interval, and a minimum of 110 days of diary entries over 26-week interval to be a responder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Responders In Irritable Bowel Syndrome, Diarrhea Predominant (IBS-d) Global Symptom Scale by Intervals</measure>
    <time_frame>12-week interval (Weeks 1-12), 26-week interval (Weeks 1-26), and 4-week interval (Weeks 1-4, 5-8, 9-12, 13-16, 17-20, and 21-24)</time_frame>
    <description>IBS-d global symptom responders were defined as those participants who met the daily IBS-d global symptom response criteria (ie, IBS-d global symptom score of 0 [none] or 1 [mild]; or a daily IBS-d global symptom score improved by ≥2.0 compared to the baseline average) for at least 50% of days with diary entries during each interval. IBS-d Global Symptom Scale was a 5 point scale, score ranging from 0 to 4. 0= no symptoms, 1= mild symptoms, 2= moderate symptoms, 3= severe symptoms and 4 = very severe symptoms. A participant must have had a minimum of 20 days of diary entries over any 4-week interval, a minimum of 60 days of diary entries over the 12-week interval, and a minimum of 110 days of diary entries over the 26-week interval to be a responder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Were Responders to the Irritable Bowel Syndrome Quality of Life Measure (IBS-QoL) Scale</measure>
    <time_frame>Weeks 4, 8, 12, 18, 26, 36, 44, and 52 (End of Treatment [EOT])</time_frame>
    <description>IBS-QoL responders were defined as participants who achieved at least a 14-point improvement in IBS-QoL total score from baseline to the applicable visit. The IBS-QoL consists of 34 items each with a 5-point response scale, where 1 generally represents better responses on items and 5 represents worse responses. The individual responses to the answered items were summed and standardized for a total score and then transformed to a 0- to 100-point (0= worst; 100=better) scale for ease of interpretation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Irritable Bowel Syndrome - Adequate Relief (IBS-AR) Scale</measure>
    <time_frame>12-week interval (Weeks 1-12) and 26-week interval (Weeks 1-26)</time_frame>
    <description>Adequate relief of IBS symptoms was assessed once weekly by participants answering the IBS-AR item in the electronic diary. IBS-AR responders were defined as participants with a weekly response of &quot;Yes&quot; to adequate relief of their IBS symptoms for at least 50% of the total weeks during the interval. A participant must have had a positive response on ≥6 weeks for the 12-week interval and ≥13 weeks for the 26-week interval, regardless of diary compliance, to be a responder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Abdominal Discomfort Scores</measure>
    <time_frame>Baseline, Weeks 4, 12 and 26</time_frame>
    <description>Symptoms of abdominal discomfort were recorded on a 0 to 10 scale, where 0 corresponded to no discomfort and 10 corresponded to worst imaginable discomfort. A negative change from Baseline indicates the discomfort decreased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Daily Abdominal Bloating Scores</measure>
    <time_frame>Baseline, Weeks 4, 12 and 26</time_frame>
    <description>Symptoms of abdominal bloating were recorded on a 0 to 10 scale, where 0 corresponded to no bloating and 10 corresponded to worst imaginable bloating. A negative change from Baseline indicates the bloating decreased.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Bowel Movements Per Day</measure>
    <time_frame>Weeks 4, 12 and 26</time_frame>
    <description>Participants recorded the number of bowel movements over 24 hours daily throughout the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Bowel Incontinence Episodes</measure>
    <time_frame>Weeks 4, 12 and 26</time_frame>
    <description>Participants recorded the number of incontinence episodes over 24 hours daily throughout the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Bowel Incontinence Free Days</measure>
    <time_frame>Weeks 4, 12 and 26</time_frame>
    <description>An incontinence free day was one where the participant reports zero incontinence episodes. The number of incontinence free days for a participant was assessed each week based on the number of reported days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Urgency Episodes Per Day</measure>
    <time_frame>Weeks 4, 12 and 26</time_frame>
    <description>Participants recorded the number of urgency episodes over 24 hours daily throughout the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IBS-QoL Total Scores</measure>
    <time_frame>Weeks 4, 8, 12, 18, 26, 36, 44, and 52 (EOT)</time_frame>
    <description>The IBS-QoL consists of 34 items each with a 5-point response scale, where 1 generally represents better responses on items and 5 represents worse responses. The individual responses to the answered items were summed and standardized for a total score and then transformed to a 0- to 100- point scale (0=worst; 100=better) for ease of interpretation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in IBS-QoL Total Scores</measure>
    <time_frame>Baseline, Weeks 4, 8, 12, 18, 26, 36, 44, and 52/EOT</time_frame>
    <description>The IBS-QoL consists of 34 items each with a 5-point response scale, where 1 generally represents better responses on items and 5 represents worse responses. The individual responses to the answered items were summed and standardized for a total score and then transformed to a 0- to 100- point scale (0=worst; 100=better) for ease of interpretation. A positive change from Baseline indicates that quality of life improved.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1282</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Eluxadoline 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 52 weeks period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eluxadoline 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 52 weeks period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 52 weeks period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eluxadoline</intervention_name>
    <description>Oral tablets twice daily</description>
    <arm_group_label>Eluxadoline 100 mg</arm_group_label>
    <arm_group_label>Eluxadoline 75 mg</arm_group_label>
    <other_name>JNJ-27018966</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablets twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Participant has a diagnosis of irritable bowel syndrome (IBS) with a subtype of
             diarrhea defined by the Rome III criteria.

          2. Participant has had a colonoscopy performed:

               -  Within 10 years prior to Prescreening if participant is at least 50 years of age
                  (sigmoidoscopy, double contrast barium enema, or computed tomography (CT)
                  colonography within the past 5 years is acceptable)

               -  Since the onset (if applicable) of any of the following alarm features for
                  participants of any age:

                    -  Participant has documented weight loss within the past 6 months

                    -  Participant has nocturnal symptoms

                    -  Participant has a familial history of first-degree relatives with colon
                       cancer or

                    -  Participant has blood mixed with their stool (excluding blood from
                       hemorrhoids).

          3. Female participants must be:

               -  Postmenopausal, defined as 52 years or older and amenorrheic for at least 2 years
                  at Prescreening,

               -  Surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal
                  ligation, or otherwise be incapable of pregnancy),

               -  Abstinent, or

               -  If sexually active, be practicing an effective method of birth control.

        Exclusion Criteria:

          1. Participant has a diagnosis of IBS with a subtype of constipation, mixed IBS, or
             unsubtyped IBS by the Rome III criteria.

          2. Participant has a history of inflammatory or immune-mediated gastrointestinal (GI)
             disorders including inflammatory bowel disease (ie, Crohn's disease, ulcerative
             colitis) and celiac disease.

          3. Participant has a history of diverticulitis within 3 months prior to Prescreening.

          4. Participant has a history of intestinal obstruction, stricture, toxic megacolon, GI
             perforation, fecal impaction, gastric banding, bariatric surgery, adhesions, ischemic
             colitis, or impaired intestinal circulation (eg, aortoiliac disease).

          5. Participant has any of the following surgical history:

               -  Cholecystectomy with any history of post cholecystectomy biliary tract pain

               -  Any abdominal surgery within the 3 months prior to Prescreening

               -  Participant has a history of major gastric, hepatic, pancreatic, or intestinal
                  surgery (appendectomy, hemorrhoidectomy, or polypectomy greater than 3 months
                  post surgery are allowed)

        Other protocol-specific eligibility criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Athens</city>
        <state>Alabama</state>
        <zip>35611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Foley</city>
        <state>Alabama</state>
        <zip>36535</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Ozark</city>
        <state>Alabama</state>
        <zip>36360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <zip>72117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Azusa</city>
        <state>California</state>
        <zip>91702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Bell Gardens</city>
        <state>California</state>
        <zip>90201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Carson</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Corona</city>
        <state>California</state>
        <zip>92880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92843</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Monterey Park</city>
        <state>California</state>
        <zip>91754</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <zip>91606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Pismo Beach</city>
        <state>California</state>
        <zip>93449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Lafayette</city>
        <state>Colorado</state>
        <zip>80026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <zip>80501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06851</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Ridgefield</city>
        <state>Connecticut</state>
        <zip>06877</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33428</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Cooper City</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Crystal River</city>
        <state>Florida</state>
        <zip>34429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33172</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Eustis</city>
        <state>Florida</state>
        <zip>32726</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furix Research Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Miami Springs</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>New Smyrna Beach</city>
        <state>Florida</state>
        <zip>32168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Oviedo</city>
        <state>Florida</state>
        <zip>32765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Palm Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33782</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Sanford</city>
        <state>Florida</state>
        <zip>32771</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Sebastian</city>
        <state>Florida</state>
        <zip>32958</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Venice</city>
        <state>Florida</state>
        <zip>34292</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Blue Ridge</city>
        <state>Georgia</state>
        <zip>30513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Johns Creek</city>
        <state>Georgia</state>
        <zip>30097</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Lilburn</city>
        <state>Georgia</state>
        <zip>30047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Oakwood</city>
        <state>Georgia</state>
        <zip>30566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Perry</city>
        <state>Georgia</state>
        <zip>31069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Eagle</city>
        <state>Idaho</state>
        <zip>83616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Addison</city>
        <state>Illinois</state>
        <zip>60101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Morton</city>
        <state>Illinois</state>
        <zip>61550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Brownsburg</city>
        <state>Indiana</state>
        <zip>46112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Clive</city>
        <state>Iowa</state>
        <zip>50325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <zip>52807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Crestview Hills</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Hawesville</city>
        <state>Kentucky</state>
        <zip>42348</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Madisonville</city>
        <state>Kentucky</state>
        <zip>42431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Baker</city>
        <state>Louisiana</state>
        <zip>70794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Hammond</city>
        <state>Louisiana</state>
        <zip>70403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Opelousas</city>
        <state>Louisiana</state>
        <zip>70570</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <zip>04401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Stevensville</city>
        <state>Michigan</state>
        <zip>49127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Chaska</city>
        <state>Minnesota</state>
        <zip>55318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <zip>68005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Collingswood</city>
        <state>New Jersey</state>
        <zip>08108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Hartsdale</city>
        <state>New York</state>
        <zip>10530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Kew Gardens</city>
        <state>New York</state>
        <zip>11415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <zip>12553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>North Massapequa</city>
        <state>New York</state>
        <zip>11758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <zip>28501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Lenoir</city>
        <state>North Carolina</state>
        <zip>28645</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Beavercreek</city>
        <state>Ohio</state>
        <zip>45432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Berea</city>
        <state>Ohio</state>
        <zip>44017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Centerville</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45419</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Englewood</city>
        <state>Ohio</state>
        <zip>45322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <zip>45005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <zip>43302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Miamisburg</city>
        <state>Ohio</state>
        <zip>45342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Wadsworth</city>
        <state>Ohio</state>
        <zip>44281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <zip>43701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Belle Vernon</city>
        <state>Pennsylvania</state>
        <zip>15012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Johnstown</city>
        <state>Pennsylvania</state>
        <zip>15905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <zip>19446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Upper Saint Clair</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Cumberland</city>
        <state>Rhode Island</state>
        <zip>02864</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Fort Mill</city>
        <state>South Carolina</state>
        <zip>29707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29588</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Simpsonville</city>
        <state>South Carolina</state>
        <zip>29681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <zip>29485</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Clarksville</city>
        <state>Tennessee</state>
        <zip>37043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Columbia</city>
        <state>Tennessee</state>
        <zip>38401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Smyrna</city>
        <state>Tennessee</state>
        <zip>37167</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Baytown</city>
        <state>Texas</state>
        <zip>77521</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Marshall</city>
        <state>Texas</state>
        <zip>75670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Clinton</city>
        <state>Utah</state>
        <zip>84015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Logan</city>
        <state>Utah</state>
        <zip>84341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Williamsburg</city>
        <state>Virginia</state>
        <zip>23185</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Kamloops</city>
        <state>British Columbia</state>
        <zip>V2C 1K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 1Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Bridgewater</city>
        <state>Nova Scotia</state>
        <zip>B4V 3N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 2M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1S 2M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Niagara Falls</city>
        <state>Ontario</state>
        <zip>L2G 1J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1H 1B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Derbyshire</state>
        <zip>S40 4AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Blackpool</city>
        <state>Lancashire</state>
        <zip>FY3 7EN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Thornton-Cleveleys</city>
        <state>Lancashire</state>
        <zip>FY5 3LF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Burbage</city>
        <state>Leicestershire</state>
        <zip>LE10 2SE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Leamington Spa</city>
        <state>Warwickshire</state>
        <zip>CV32 4RA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Chippenham</city>
        <state>Wiltshire</state>
        <zip>SN14 6GT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Bath</city>
        <zip>BA2 3HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Bath</city>
        <zip>BA2 4BY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Coventry</city>
        <zip>CV6 4DD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Dorking</city>
        <zip>RH4 1SD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Haxey</city>
        <zip>DN9 2HY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>London</city>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Shrewsbury</city>
        <zip>SY3 8XQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Strensall</city>
        <zip>YO32 5UA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Thornton</city>
        <zip>FY5 2TZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Furiex Research Site</name>
      <address>
        <city>Torpoint</city>
        <zip>PL11 2JW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>March 8, 2012</study_first_submitted>
  <study_first_submitted_qc>March 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2012</study_first_posted>
  <results_first_submitted>June 11, 2018</results_first_submitted>
  <results_first_submitted_qc>August 3, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 4, 2018</results_first_posted>
  <disposition_first_submitted>March 25, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>March 25, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 21, 2014</disposition_first_posted>
  <last_update_submitted>August 3, 2018</last_update_submitted>
  <last_update_submitted_qc>August 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eluxadoline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Eluxadoline 75 mg</title>
          <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 52 weeks period.</description>
        </group>
        <group group_id="P2">
          <title>Eluxadoline 100 mg</title>
          <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 52 weeks period.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 52 weeks period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="429"/>
                <participants group_id="P2" count="426"/>
                <participants group_id="P3" count="427"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Attended Week 12 Visit</title>
              <participants_list>
                <participants group_id="P1" count="341"/>
                <participants group_id="P2" count="330"/>
                <participants group_id="P3" count="342"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Attended Week 26 Visit</title>
              <participants_list>
                <participants group_id="P1" count="289"/>
                <participants group_id="P2" count="291"/>
                <participants group_id="P3" count="290"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="257"/>
                <participants group_id="P2" count="257"/>
                <participants group_id="P3" count="269"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="172"/>
                <participants group_id="P2" count="169"/>
                <participants group_id="P3" count="158"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Voluntarily withdrew</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="79"/>
                <participants group_id="P3" count="96"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician decision: other</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician decision: lack of efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized and never dispensed drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Enrolled Set included 1282 participants who were randomized or received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Eluxadoline 75 mg</title>
          <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 52 weeks period.</description>
        </group>
        <group group_id="B2">
          <title>Eluxadoline 100 mg</title>
          <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 52 weeks period.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 52 weeks period.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="429"/>
            <count group_id="B2" value="426"/>
            <count group_id="B3" value="427"/>
            <count group_id="B4" value="1282"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="429"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="427"/>
                    <count group_id="B4" value="1282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.5" spread="13.18"/>
                    <measurement group_id="B2" value="44.4" spread="13.91"/>
                    <measurement group_id="B3" value="45.8" spread="14.10"/>
                    <measurement group_id="B4" value="44.9" spread="13.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>18-40 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="429"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="427"/>
                    <count group_id="B4" value="1282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173"/>
                    <measurement group_id="B2" value="166"/>
                    <measurement group_id="B3" value="159"/>
                    <measurement group_id="B4" value="498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>41-64 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="429"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="427"/>
                    <count group_id="B4" value="1282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="227"/>
                    <measurement group_id="B2" value="225"/>
                    <measurement group_id="B3" value="217"/>
                    <measurement group_id="B4" value="669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥65 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="429"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="427"/>
                    <count group_id="B4" value="1282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="429"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="427"/>
                    <count group_id="B4" value="1282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="278"/>
                    <measurement group_id="B2" value="283"/>
                    <measurement group_id="B3" value="277"/>
                    <measurement group_id="B4" value="838"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="150"/>
                    <measurement group_id="B4" value="444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="429"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="427"/>
                    <count group_id="B4" value="1282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="374"/>
                    <measurement group_id="B2" value="368"/>
                    <measurement group_id="B3" value="370"/>
                    <measurement group_id="B4" value="1112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="429"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="427"/>
                    <count group_id="B4" value="1282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="429"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="427"/>
                    <count group_id="B4" value="1282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="429"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="427"/>
                    <count group_id="B4" value="1282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="429"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="427"/>
                    <count group_id="B4" value="1282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="429"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="427"/>
                    <count group_id="B4" value="1282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="429"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="427"/>
                    <count group_id="B4" value="1282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="125"/>
                    <measurement group_id="B4" value="361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="429"/>
                    <count group_id="B2" value="426"/>
                    <count group_id="B3" value="427"/>
                    <count group_id="B4" value="1282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="310"/>
                    <measurement group_id="B2" value="309"/>
                    <measurement group_id="B3" value="302"/>
                    <measurement group_id="B4" value="921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <population>The number analyzed indicates number of participants analyzed for this baseline characteristics.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="428"/>
                    <count group_id="B2" value="424"/>
                    <count group_id="B3" value="425"/>
                    <count group_id="B4" value="1277"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.70" spread="7.421"/>
                    <measurement group_id="B2" value="31.22" spread="7.858"/>
                    <measurement group_id="B3" value="30.63" spread="7.253"/>
                    <measurement group_id="B4" value="30.85" spread="7.513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain And Daily Stool Consistency Scores</title>
        <description>Composite responders were defined as a participant who met the daily response criteria for at least 50% of the days with diary entries during the interval of interest. A participant must had met both of the following criteria on a given day to be a daily responder: 1) Daily pain response: worst abdominal pain scores in the past 24 hours improved by ≥30% compared to baseline (average of daily worst abdominal pain the week prior to randomization). 2) Daily stool consistency response: Bristol Stool Scale (BSS) score &lt;5 (ie, score of 1, 2, 3, or 4) or the absence of a bowel movement if accompanied by ≥30% improvement in worst abdominal pain compared to baseline pain. Bristol stool scale was defined as 7-point Scale in which a score of 1 = separate hard lumps, 2 = sausage shaped but lumpy, 3 = sausage-like with cracks on the surface, 4 = sausage-like but smooth and soft, 5 = soft blobs with clear cut edges, 6 = fluffy pieces with ragged edges, and 7 = watery with no solid pieces.</description>
        <time_frame>Up to 12 Weeks</time_frame>
        <population>Intent to Treat (ITT) analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain And Daily Stool Consistency Scores</title>
          <description>Composite responders were defined as a participant who met the daily response criteria for at least 50% of the days with diary entries during the interval of interest. A participant must had met both of the following criteria on a given day to be a daily responder: 1) Daily pain response: worst abdominal pain scores in the past 24 hours improved by ≥30% compared to baseline (average of daily worst abdominal pain the week prior to randomization). 2) Daily stool consistency response: Bristol Stool Scale (BSS) score &lt;5 (ie, score of 1, 2, 3, or 4) or the absence of a bowel movement if accompanied by ≥30% improvement in worst abdominal pain compared to baseline pain. Bristol stool scale was defined as 7-point Scale in which a score of 1 = separate hard lumps, 2 = sausage shaped but lumpy, 3 = sausage-like with cracks on the surface, 4 = sausage-like but smooth and soft, 5 = soft blobs with clear cut edges, 6 = fluffy pieces with ragged edges, and 7 = watery with no solid pieces.</description>
          <population>Intent to Treat (ITT) analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="427"/>
                <count group_id="O2" value="426"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9"/>
                    <measurement group_id="O2" value="25.1"/>
                    <measurement group_id="O3" value="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The family-wise error rate was controlled by Bonferroni adjustment for each active dose versus placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.014</p_value>
            <p_value_desc>Significance level of 0.025</p_value_desc>
            <method>Chi-square test statistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The family-wise error rate was controlled by Bonferroni adjustment for each active dose versus placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>Significance level of 0.025</p_value_desc>
            <method>Chi-square test statistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain And Daily Stool Consistency Scores</title>
        <description>Composite responders were defined as a participant who met the daily response criteria for at least 50% of the days with diary entries during the interval of interest. A participant must had met both of the following criteria on a given day to be a daily responder: 1) Daily pain response: worst abdominal pain scores in the past 24 hours improved by ≥30% compared to baseline (average of daily worst abdominal pain the week prior to randomization). 2) Daily stool consistency response: Bristol Stool Scale (BSS) score &lt;5 (ie, score of 1, 2, 3, or 4) or the absence of a bowel movement if accompanied by ≥30% improvement in worst abdominal pain compared to baseline pain. Bristol stool scale was defined as 7-point Scale in which a score of 1 = separate hard lumps, 2 = sausage shaped but lumpy, 3 = sausage-like with cracks on the surface, 4 = sausage-like but smooth and soft, 5 = soft blobs with clear cut edges, 6 = fluffy pieces with ragged edges, and 7 = watery with no solid pieces.</description>
        <time_frame>Up to 26 Weeks</time_frame>
        <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain And Daily Stool Consistency Scores</title>
          <description>Composite responders were defined as a participant who met the daily response criteria for at least 50% of the days with diary entries during the interval of interest. A participant must had met both of the following criteria on a given day to be a daily responder: 1) Daily pain response: worst abdominal pain scores in the past 24 hours improved by ≥30% compared to baseline (average of daily worst abdominal pain the week prior to randomization). 2) Daily stool consistency response: Bristol Stool Scale (BSS) score &lt;5 (ie, score of 1, 2, 3, or 4) or the absence of a bowel movement if accompanied by ≥30% improvement in worst abdominal pain compared to baseline pain. Bristol stool scale was defined as 7-point Scale in which a score of 1 = separate hard lumps, 2 = sausage shaped but lumpy, 3 = sausage-like with cracks on the surface, 4 = sausage-like but smooth and soft, 5 = soft blobs with clear cut edges, 6 = fluffy pieces with ragged edges, and 7 = watery with no solid pieces.</description>
          <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="427"/>
                <count group_id="O2" value="426"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4"/>
                    <measurement group_id="O2" value="29.3"/>
                    <measurement group_id="O3" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The family-wise error rate was controlled by Bonferroni adjustment for each active dose versus placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.112</p_value>
            <p_value_desc>Significance level of 0.025</p_value_desc>
            <method>Chi-square test statistic</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The family-wise error rate was controlled by Bonferroni adjustment for each active dose versus placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Significance level of 0.025</p_value_desc>
            <method>Chi-square test statistic</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Pain Responders In Daily Worst Abdominal Pain Scores by Intervals</title>
        <description>Pain responders were defined as participants who met the daily pain response criteria (ie, the worst abdominal pain score in the past 24 hours improved by ≥30% compared to baseline) for at least 50% of days with diary entries during each interval. A participant must have had a minimum of 20 days of diary entries over any 4-week interval, a minimum of 60 days of diary entries over the 12-week interval, and a minimum of 110 days of diary entries over the 26-week interval to be a responder.</description>
        <time_frame>12-week interval (Weeks 1-12), 26-week interval (Weeks 1-26), and 4-week interval (Weeks 1-4, 5-8, 9-12, 13-16, 17-20, and 21-24)</time_frame>
        <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Pain Responders In Daily Worst Abdominal Pain Scores by Intervals</title>
          <description>Pain responders were defined as participants who met the daily pain response criteria (ie, the worst abdominal pain score in the past 24 hours improved by ≥30% compared to baseline) for at least 50% of days with diary entries during each interval. A participant must have had a minimum of 20 days of diary entries over any 4-week interval, a minimum of 60 days of diary entries over the 12-week interval, and a minimum of 110 days of diary entries over the 26-week interval to be a responder.</description>
          <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="427"/>
                <count group_id="O2" value="426"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders during Weeks 1-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.4"/>
                    <measurement group_id="O2" value="43.2"/>
                    <measurement group_id="O3" value="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 1-26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2"/>
                    <measurement group_id="O2" value="46.5"/>
                    <measurement group_id="O3" value="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 1-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5"/>
                    <measurement group_id="O2" value="44.4"/>
                    <measurement group_id="O3" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 5-8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5"/>
                    <measurement group_id="O2" value="47.2"/>
                    <measurement group_id="O3" value="45.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 9-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5"/>
                    <measurement group_id="O2" value="45.8"/>
                    <measurement group_id="O3" value="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 13-16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3"/>
                    <measurement group_id="O2" value="44.1"/>
                    <measurement group_id="O3" value="45.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 17-20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7"/>
                    <measurement group_id="O2" value="43.2"/>
                    <measurement group_id="O3" value="41.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 21-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7"/>
                    <measurement group_id="O2" value="42.0"/>
                    <measurement group_id="O3" value="38.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Responders In Daily Stool Consistency Scores by Intervals</title>
        <description>Stool consistency responders: participants who met daily stool consistency response criterion (ie,score of 1, 2, 3, or 4 or absence of bowel movement if accompanied by ≥30% improvement in worst abdominal pain compared to baseline pain) for at least 50% of days with diary entries during each interval. BSS was defined as 7-point Scale in which score of 1= separate hard lumps, 2= sausage shaped but lumpy, 3= sausage-like with cracks on the surface, 4= sausage-like but smooth and soft, 5= soft blobs with clear cut edges, 6= fluffy pieces with ragged edges, and 7= watery with no solid pieces. A participant must have had a minimum of 20 days of diary entries over any 4-week interval, a minimum of 60 days of diary entries over 12-week interval, and a minimum of 110 days of diary entries over 26-week interval to be a responder.</description>
        <time_frame>12-week interval (Weeks 1-12), 26-week interval (Weeks 1-26), and 4-week interval (Weeks 1-4, 5-8, 9-12, 13-16, 17-20, and 21-24)</time_frame>
        <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Responders In Daily Stool Consistency Scores by Intervals</title>
          <description>Stool consistency responders: participants who met daily stool consistency response criterion (ie,score of 1, 2, 3, or 4 or absence of bowel movement if accompanied by ≥30% improvement in worst abdominal pain compared to baseline pain) for at least 50% of days with diary entries during each interval. BSS was defined as 7-point Scale in which score of 1= separate hard lumps, 2= sausage shaped but lumpy, 3= sausage-like with cracks on the surface, 4= sausage-like but smooth and soft, 5= soft blobs with clear cut edges, 6= fluffy pieces with ragged edges, and 7= watery with no solid pieces. A participant must have had a minimum of 20 days of diary entries over any 4-week interval, a minimum of 60 days of diary entries over 12-week interval, and a minimum of 110 days of diary entries over 26-week interval to be a responder.</description>
          <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="427"/>
                <count group_id="O2" value="426"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders during Weeks 1-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0"/>
                    <measurement group_id="O2" value="34.3"/>
                    <measurement group_id="O3" value="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 1-26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1"/>
                    <measurement group_id="O2" value="34.0"/>
                    <measurement group_id="O3" value="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 1-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8"/>
                    <measurement group_id="O2" value="31.5"/>
                    <measurement group_id="O3" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 5-8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1"/>
                    <measurement group_id="O2" value="35.2"/>
                    <measurement group_id="O3" value="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 9-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.0"/>
                    <measurement group_id="O2" value="35.2"/>
                    <measurement group_id="O3" value="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 13-16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6"/>
                    <measurement group_id="O2" value="32.9"/>
                    <measurement group_id="O3" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 17-20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.9"/>
                    <measurement group_id="O2" value="31.5"/>
                    <measurement group_id="O3" value="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 21-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2"/>
                    <measurement group_id="O2" value="30.3"/>
                    <measurement group_id="O3" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Responders In Irritable Bowel Syndrome, Diarrhea Predominant (IBS-d) Global Symptom Scale by Intervals</title>
        <description>IBS-d global symptom responders were defined as those participants who met the daily IBS-d global symptom response criteria (ie, IBS-d global symptom score of 0 [none] or 1 [mild]; or a daily IBS-d global symptom score improved by ≥2.0 compared to the baseline average) for at least 50% of days with diary entries during each interval. IBS-d Global Symptom Scale was a 5 point scale, score ranging from 0 to 4. 0= no symptoms, 1= mild symptoms, 2= moderate symptoms, 3= severe symptoms and 4 = very severe symptoms. A participant must have had a minimum of 20 days of diary entries over any 4-week interval, a minimum of 60 days of diary entries over the 12-week interval, and a minimum of 110 days of diary entries over the 26-week interval to be a responder.</description>
        <time_frame>12-week interval (Weeks 1-12), 26-week interval (Weeks 1-26), and 4-week interval (Weeks 1-4, 5-8, 9-12, 13-16, 17-20, and 21-24)</time_frame>
        <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Responders In Irritable Bowel Syndrome, Diarrhea Predominant (IBS-d) Global Symptom Scale by Intervals</title>
          <description>IBS-d global symptom responders were defined as those participants who met the daily IBS-d global symptom response criteria (ie, IBS-d global symptom score of 0 [none] or 1 [mild]; or a daily IBS-d global symptom score improved by ≥2.0 compared to the baseline average) for at least 50% of days with diary entries during each interval. IBS-d Global Symptom Scale was a 5 point scale, score ranging from 0 to 4. 0= no symptoms, 1= mild symptoms, 2= moderate symptoms, 3= severe symptoms and 4 = very severe symptoms. A participant must have had a minimum of 20 days of diary entries over any 4-week interval, a minimum of 60 days of diary entries over the 12-week interval, and a minimum of 110 days of diary entries over the 26-week interval to be a responder.</description>
          <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="427"/>
                <count group_id="O2" value="426"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders during Weeks 1-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1"/>
                    <measurement group_id="O2" value="34.7"/>
                    <measurement group_id="O3" value="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 1-26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3"/>
                    <measurement group_id="O2" value="37.1"/>
                    <measurement group_id="O3" value="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 1-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6"/>
                    <measurement group_id="O2" value="31.9"/>
                    <measurement group_id="O3" value="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 5-8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0"/>
                    <measurement group_id="O2" value="38.7"/>
                    <measurement group_id="O3" value="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 9-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.6"/>
                    <measurement group_id="O2" value="36.6"/>
                    <measurement group_id="O3" value="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 13-16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8"/>
                    <measurement group_id="O2" value="35.9"/>
                    <measurement group_id="O3" value="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 17-20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5"/>
                    <measurement group_id="O2" value="36.4"/>
                    <measurement group_id="O3" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 21-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8"/>
                    <measurement group_id="O2" value="35.2"/>
                    <measurement group_id="O3" value="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Were Responders to the Irritable Bowel Syndrome Quality of Life Measure (IBS-QoL) Scale</title>
        <description>IBS-QoL responders were defined as participants who achieved at least a 14-point improvement in IBS-QoL total score from baseline to the applicable visit. The IBS-QoL consists of 34 items each with a 5-point response scale, where 1 generally represents better responses on items and 5 represents worse responses. The individual responses to the answered items were summed and standardized for a total score and then transformed to a 0- to 100-point (0= worst; 100=better) scale for ease of interpretation.</description>
        <time_frame>Weeks 4, 8, 12, 18, 26, 36, 44, and 52 (End of Treatment [EOT])</time_frame>
        <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Were Responders to the Irritable Bowel Syndrome Quality of Life Measure (IBS-QoL) Scale</title>
          <description>IBS-QoL responders were defined as participants who achieved at least a 14-point improvement in IBS-QoL total score from baseline to the applicable visit. The IBS-QoL consists of 34 items each with a 5-point response scale, where 1 generally represents better responses on items and 5 represents worse responses. The individual responses to the answered items were summed and standardized for a total score and then transformed to a 0- to 100-point (0= worst; 100=better) scale for ease of interpretation.</description>
          <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="427"/>
                <count group_id="O2" value="426"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.6"/>
                    <measurement group_id="O2" value="44.1"/>
                    <measurement group_id="O3" value="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.8"/>
                    <measurement group_id="O2" value="49.8"/>
                    <measurement group_id="O3" value="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3"/>
                    <measurement group_id="O2" value="48.1"/>
                    <measurement group_id="O3" value="44.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders at Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5"/>
                    <measurement group_id="O2" value="45.1"/>
                    <measurement group_id="O3" value="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders at Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.4"/>
                    <measurement group_id="O2" value="45.1"/>
                    <measurement group_id="O3" value="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders at Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0"/>
                    <measurement group_id="O2" value="43.2"/>
                    <measurement group_id="O3" value="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders at Week 44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.6"/>
                    <measurement group_id="O2" value="40.1"/>
                    <measurement group_id="O3" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders at Week 52/EOT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.4"/>
                    <measurement group_id="O2" value="54.9"/>
                    <measurement group_id="O3" value="47.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Irritable Bowel Syndrome - Adequate Relief (IBS-AR) Scale</title>
        <description>Adequate relief of IBS symptoms was assessed once weekly by participants answering the IBS-AR item in the electronic diary. IBS-AR responders were defined as participants with a weekly response of &quot;Yes&quot; to adequate relief of their IBS symptoms for at least 50% of the total weeks during the interval. A participant must have had a positive response on ≥6 weeks for the 12-week interval and ≥13 weeks for the 26-week interval, regardless of diary compliance, to be a responder.</description>
        <time_frame>12-week interval (Weeks 1-12) and 26-week interval (Weeks 1-26)</time_frame>
        <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Irritable Bowel Syndrome - Adequate Relief (IBS-AR) Scale</title>
          <description>Adequate relief of IBS symptoms was assessed once weekly by participants answering the IBS-AR item in the electronic diary. IBS-AR responders were defined as participants with a weekly response of &quot;Yes&quot; to adequate relief of their IBS symptoms for at least 50% of the total weeks during the interval. A participant must have had a positive response on ≥6 weeks for the 12-week interval and ≥13 weeks for the 26-week interval, regardless of diary compliance, to be a responder.</description>
          <population>ITT analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="427"/>
                <count group_id="O2" value="426"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders during Weeks 1-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.9"/>
                    <measurement group_id="O2" value="54.2"/>
                    <measurement group_id="O3" value="43.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders during Weeks 1-26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.7"/>
                    <measurement group_id="O2" value="49.5"/>
                    <measurement group_id="O3" value="40.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Abdominal Discomfort Scores</title>
        <description>Symptoms of abdominal discomfort were recorded on a 0 to 10 scale, where 0 corresponded to no discomfort and 10 corresponded to worst imaginable discomfort. A negative change from Baseline indicates the discomfort decreased.</description>
        <time_frame>Baseline, Weeks 4, 12 and 26</time_frame>
        <population>Intent to Treat (ITT) analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Abdominal Discomfort Scores</title>
          <description>Symptoms of abdominal discomfort were recorded on a 0 to 10 scale, where 0 corresponded to no discomfort and 10 corresponded to worst imaginable discomfort. A negative change from Baseline indicates the discomfort decreased.</description>
          <population>Intent to Treat (ITT) analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="427"/>
                <count group_id="O2" value="426"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="392"/>
                    <count group_id="O2" value="381"/>
                    <count group_id="O3" value="401"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.24" spread="2.204"/>
                    <measurement group_id="O2" value="-2.41" spread="2.326"/>
                    <measurement group_id="O3" value="-2.01" spread="2.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="338"/>
                    <count group_id="O2" value="335"/>
                    <count group_id="O3" value="335"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.75" spread="2.534"/>
                    <measurement group_id="O2" value="-2.97" spread="2.526"/>
                    <measurement group_id="O3" value="-2.61" spread="2.444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="264"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.27" spread="2.578"/>
                    <measurement group_id="O2" value="-3.52" spread="2.543"/>
                    <measurement group_id="O3" value="-3.00" spread="2.579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Daily Abdominal Bloating Scores</title>
        <description>Symptoms of abdominal bloating were recorded on a 0 to 10 scale, where 0 corresponded to no bloating and 10 corresponded to worst imaginable bloating. A negative change from Baseline indicates the bloating decreased.</description>
        <time_frame>Baseline, Weeks 4, 12 and 26</time_frame>
        <population>Intent to Treat (ITT) analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Daily Abdominal Bloating Scores</title>
          <description>Symptoms of abdominal bloating were recorded on a 0 to 10 scale, where 0 corresponded to no bloating and 10 corresponded to worst imaginable bloating. A negative change from Baseline indicates the bloating decreased.</description>
          <population>Intent to Treat (ITT) analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="427"/>
                <count group_id="O2" value="426"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="330"/>
                    <count group_id="O2" value="318"/>
                    <count group_id="O3" value="329"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.84" spread="2.303"/>
                    <measurement group_id="O2" value="-2.03" spread="2.333"/>
                    <measurement group_id="O3" value="-1.72" spread="2.303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="277"/>
                    <count group_id="O2" value="272"/>
                    <count group_id="O3" value="274"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.42" spread="2.616"/>
                    <measurement group_id="O2" value="-2.49" spread="2.533"/>
                    <measurement group_id="O3" value="-2.16" spread="2.544"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="209"/>
                    <count group_id="O2" value="210"/>
                    <count group_id="O3" value="210"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.76" spread="2.823"/>
                    <measurement group_id="O2" value="-2.94" spread="2.576"/>
                    <measurement group_id="O3" value="-2.47" spread="2.562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Bowel Movements Per Day</title>
        <description>Participants recorded the number of bowel movements over 24 hours daily throughout the treatment.</description>
        <time_frame>Weeks 4, 12 and 26</time_frame>
        <population>Intent to Treat (ITT) analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Bowel Movements Per Day</title>
          <description>Participants recorded the number of bowel movements over 24 hours daily throughout the treatment.</description>
          <population>Intent to Treat (ITT) analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
          <units>bowel movements per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="427"/>
                <count group_id="O2" value="426"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="392"/>
                    <count group_id="O2" value="381"/>
                    <count group_id="O3" value="401"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.20" spread="2.090"/>
                    <measurement group_id="O2" value="3.20" spread="2.236"/>
                    <measurement group_id="O3" value="3.72" spread="2.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="338"/>
                    <count group_id="O2" value="335"/>
                    <count group_id="O3" value="335"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.12" spread="2.143"/>
                    <measurement group_id="O2" value="3.09" spread="2.318"/>
                    <measurement group_id="O3" value="3.44" spread="1.987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="264"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" spread="2.158"/>
                    <measurement group_id="O2" value="2.79" spread="2.270"/>
                    <measurement group_id="O3" value="3.12" spread="1.831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Bowel Incontinence Episodes</title>
        <description>Participants recorded the number of incontinence episodes over 24 hours daily throughout the treatment.</description>
        <time_frame>Weeks 4, 12 and 26</time_frame>
        <population>Intent to Treat (ITT) analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Bowel Incontinence Episodes</title>
          <description>Participants recorded the number of incontinence episodes over 24 hours daily throughout the treatment.</description>
          <population>Intent to Treat (ITT) analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
          <units>incontinence episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="427"/>
                <count group_id="O2" value="426"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="392"/>
                    <count group_id="O2" value="381"/>
                    <count group_id="O3" value="401"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" spread="1.603"/>
                    <measurement group_id="O2" value="0.72" spread="1.534"/>
                    <measurement group_id="O3" value="0.93" spread="2.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="338"/>
                    <count group_id="O2" value="335"/>
                    <count group_id="O3" value="335"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="1.542"/>
                    <measurement group_id="O2" value="0.71" spread="1.663"/>
                    <measurement group_id="O3" value="0.94" spread="3.612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="264"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="1.298"/>
                    <measurement group_id="O2" value="0.58" spread="1.358"/>
                    <measurement group_id="O3" value="0.69" spread="1.500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Bowel Incontinence Free Days</title>
        <description>An incontinence free day was one where the participant reports zero incontinence episodes. The number of incontinence free days for a participant was assessed each week based on the number of reported days.</description>
        <time_frame>Weeks 4, 12 and 26</time_frame>
        <population>Intent to Treat (ITT) analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Bowel Incontinence Free Days</title>
          <description>An incontinence free day was one where the participant reports zero incontinence episodes. The number of incontinence free days for a participant was assessed each week based on the number of reported days.</description>
          <population>Intent to Treat (ITT) analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="427"/>
                <count group_id="O2" value="426"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="392"/>
                    <count group_id="O2" value="381"/>
                    <count group_id="O3" value="401"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.83" spread="2.745"/>
                    <measurement group_id="O2" value="4.95" spread="2.618"/>
                    <measurement group_id="O3" value="4.63" spread="2.741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="338"/>
                    <count group_id="O2" value="335"/>
                    <count group_id="O3" value="335"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.96" spread="2.672"/>
                    <measurement group_id="O2" value="4.79" spread="2.671"/>
                    <measurement group_id="O3" value="4.64" spread="2.704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="264"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.39" spread="2.465"/>
                    <measurement group_id="O2" value="4.35" spread="2.449"/>
                    <measurement group_id="O3" value="4.00" spread="2.539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Urgency Episodes Per Day</title>
        <description>Participants recorded the number of urgency episodes over 24 hours daily throughout the treatment.</description>
        <time_frame>Weeks 4, 12 and 26</time_frame>
        <population>Intent to Treat (ITT) analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Urgency Episodes Per Day</title>
          <description>Participants recorded the number of urgency episodes over 24 hours daily throughout the treatment.</description>
          <population>Intent to Treat (ITT) analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
          <units>episodes per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="427"/>
                <count group_id="O2" value="426"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="392"/>
                    <count group_id="O2" value="381"/>
                    <count group_id="O3" value="401"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="1.840"/>
                    <measurement group_id="O2" value="1.74" spread="1.879"/>
                    <measurement group_id="O3" value="2.19" spread="2.082"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="338"/>
                    <count group_id="O2" value="335"/>
                    <count group_id="O3" value="335"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.55" spread="1.777"/>
                    <measurement group_id="O2" value="1.60" spread="1.995"/>
                    <measurement group_id="O3" value="1.81" spread="1.883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="264"/>
                    <count group_id="O2" value="262"/>
                    <count group_id="O3" value="264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="1.773"/>
                    <measurement group_id="O2" value="1.45" spread="2.113"/>
                    <measurement group_id="O3" value="1.55" spread="1.853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IBS-QoL Total Scores</title>
        <description>The IBS-QoL consists of 34 items each with a 5-point response scale, where 1 generally represents better responses on items and 5 represents worse responses. The individual responses to the answered items were summed and standardized for a total score and then transformed to a 0- to 100- point scale (0=worst; 100=better) for ease of interpretation.</description>
        <time_frame>Weeks 4, 8, 12, 18, 26, 36, 44, and 52 (EOT)</time_frame>
        <population>Intent to Treat (ITT) analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
        </group_list>
        <measure>
          <title>IBS-QoL Total Scores</title>
          <description>The IBS-QoL consists of 34 items each with a 5-point response scale, where 1 generally represents better responses on items and 5 represents worse responses. The individual responses to the answered items were summed and standardized for a total score and then transformed to a 0- to 100- point scale (0=worst; 100=better) for ease of interpretation.</description>
          <population>Intent to Treat (ITT) analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="427"/>
                <count group_id="O2" value="426"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="384"/>
                    <count group_id="O2" value="371"/>
                    <count group_id="O3" value="392"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.37" spread="23.747"/>
                    <measurement group_id="O2" value="64.34" spread="24.049"/>
                    <measurement group_id="O3" value="57.13" spread="24.318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="354"/>
                    <count group_id="O2" value="354"/>
                    <count group_id="O3" value="360"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.22" spread="23.919"/>
                    <measurement group_id="O2" value="67.73" spread="23.421"/>
                    <measurement group_id="O3" value="59.46" spread="24.323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="339"/>
                    <count group_id="O2" value="330"/>
                    <count group_id="O3" value="342"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.80" spread="24.131"/>
                    <measurement group_id="O2" value="68.93" spread="23.938"/>
                    <measurement group_id="O3" value="61.72" spread="25.545"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders at Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="315"/>
                    <count group_id="O2" value="312"/>
                    <count group_id="O3" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.75" spread="23.902"/>
                    <measurement group_id="O2" value="70.05" spread="23.662"/>
                    <measurement group_id="O3" value="63.60" spread="24.618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders at Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="288"/>
                    <count group_id="O2" value="291"/>
                    <count group_id="O3" value="290"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.74" spread="23.312"/>
                    <measurement group_id="O2" value="71.34" spread="23.106"/>
                    <measurement group_id="O3" value="64.83" spread="24.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="277"/>
                    <count group_id="O2" value="272"/>
                    <count group_id="O3" value="278"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.53" spread="23.043"/>
                    <measurement group_id="O2" value="72.37" spread="23.246"/>
                    <measurement group_id="O3" value="66.47" spread="24.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders at Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="267"/>
                    <count group_id="O2" value="261"/>
                    <count group_id="O3" value="271"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.30" spread="24.408"/>
                    <measurement group_id="O2" value="72.15" spread="24.398"/>
                    <measurement group_id="O3" value="65.59" spread="25.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders at Week 52/EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="351"/>
                    <count group_id="O2" value="353"/>
                    <count group_id="O3" value="362"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.85" spread="24.754"/>
                    <measurement group_id="O2" value="71.02" spread="24.294"/>
                    <measurement group_id="O3" value="63.93" spread="26.359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in IBS-QoL Total Scores</title>
        <description>The IBS-QoL consists of 34 items each with a 5-point response scale, where 1 generally represents better responses on items and 5 represents worse responses. The individual responses to the answered items were summed and standardized for a total score and then transformed to a 0- to 100- point scale (0=worst; 100=better) for ease of interpretation. A positive change from Baseline indicates that quality of life improved.</description>
        <time_frame>Baseline, Weeks 4, 8, 12, 18, 26, 36, 44, and 52/EOT</time_frame>
        <population>Intent to Treat (ITT) analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Eluxadoline 75 mg</title>
            <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O2">
            <title>Eluxadoline 100 mg</title>
            <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 52 weeks period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in IBS-QoL Total Scores</title>
          <description>The IBS-QoL consists of 34 items each with a 5-point response scale, where 1 generally represents better responses on items and 5 represents worse responses. The individual responses to the answered items were summed and standardized for a total score and then transformed to a 0- to 100- point scale (0=worst; 100=better) for ease of interpretation. A positive change from Baseline indicates that quality of life improved.</description>
          <population>Intent to Treat (ITT) analysis set included all participants who were randomized into a treatment group and presents data for participants according to their randomization assignment. Here, number analyzed is the participants who were evaluable at specific time point.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="427"/>
                <count group_id="O2" value="426"/>
                <count group_id="O3" value="427"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="382"/>
                    <count group_id="O2" value="371"/>
                    <count group_id="O3" value="392"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.49" spread="20.693"/>
                    <measurement group_id="O2" value="17.86" spread="20.191"/>
                    <measurement group_id="O3" value="13.25" spread="18.475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="353"/>
                    <count group_id="O2" value="354"/>
                    <count group_id="O3" value="360"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.88" spread="21.855"/>
                    <measurement group_id="O2" value="21.08" spread="21.347"/>
                    <measurement group_id="O3" value="15.76" spread="19.398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="337"/>
                    <count group_id="O2" value="330"/>
                    <count group_id="O3" value="342"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.26" spread="23.412"/>
                    <measurement group_id="O2" value="22.76" spread="22.592"/>
                    <measurement group_id="O3" value="17.76" spread="21.523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="313"/>
                    <count group_id="O2" value="312"/>
                    <count group_id="O3" value="315"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.09" spread="23.846"/>
                    <measurement group_id="O2" value="24.18" spread="23.025"/>
                    <measurement group_id="O3" value="19.80" spread="22.368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="288"/>
                    <count group_id="O2" value="291"/>
                    <count group_id="O3" value="290"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.28" spread="23.679"/>
                    <measurement group_id="O2" value="25.80" spread="23.998"/>
                    <measurement group_id="O3" value="20.62" spread="22.306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="277"/>
                    <count group_id="O2" value="272"/>
                    <count group_id="O3" value="278"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.37" spread="24.603"/>
                    <measurement group_id="O2" value="27.18" spread="24.201"/>
                    <measurement group_id="O3" value="22.64" spread="23.414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="267"/>
                    <count group_id="O2" value="261"/>
                    <count group_id="O3" value="271"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.13" spread="24.948"/>
                    <measurement group_id="O2" value="26.64" spread="25.017"/>
                    <measurement group_id="O3" value="21.77" spread="23.977"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52/EOT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="349"/>
                    <count group_id="O2" value="353"/>
                    <count group_id="O3" value="362"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.30" spread="23.959"/>
                    <measurement group_id="O2" value="25.86" spread="23.854"/>
                    <measurement group_id="O3" value="20.66" spread="23.956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 54 weeks</time_frame>
      <desc>The Safety Analysis Set included enrolled participants who received at least one dose of study drug and presents data according to the actual treatment received. A total of 53 participants were randomized to the Eluxadoline 75 mg arm but received Eluxadoline 100 mg due to site misallocations, these participants were included in Eluxadoline 100 mg arm. Therefore, the number of participants in the Eluxadoline 100 mg arm were more than the number of participants who were randomized to this arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>Eluxadoline 75 mg</title>
          <description>Eluxadoline 75 mg tablets, orally, twice daily for up to 52 weeks period.</description>
        </group>
        <group group_id="E2">
          <title>Eluxadoline 100 mg</title>
          <description>Eluxadoline 100 mg tablets, orally, twice daily for up to 52 weeks period.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Eluxadoline placebo matching tablets, orally, twice daily for up to 52 weeks period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Papilloedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal hemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Subdural hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Liposarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Primary progressive multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneousa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="427"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="428"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="479"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="427"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor will work with the Investigators to determine how any manuscript or publication in a scientific journal is written and edited, the number and order of authors, the publication to which it will be submitted, and other related issues. The sponsor has final approval authority over all such issues. Data are the property of the sponsor and cannot be published without prior authorization from the sponsor, but data and publication thereof will not be unduly withheld.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Allergan</organization>
      <phone>714-246-4500</phone>
      <email>clinicaltrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

